Clinical Management and Prevention of Sudden Cardiac Death

Omair Yousuf, Jonathan Chrispin, Gordon F. Tomaselli, Ronald D. Berger

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Despite the revolutionary advancements in the past 3 decades in the treatment of ventricular tachyarrhythmias with device-based therapy, sudden cardiac death (SCD) remains an enormous public health burden. Survivors of SCD are generally at high risk for recurrent events. The clinical management of such patients requires a multidisciplinary approach from postresuscitative care to a thorough cardiovascular investigation in an attempt to identify the underlying substrate, with potential to eliminate or modify the triggers through catheter ablation and ultimately an implantable cardioverter-defibrillator (ICD) for prompt treatment of recurrences in those at risk. Early recognition of low left ventricular ejection fraction as a strong predictor of death and association of ventricular arrhythmias with sudden death led to significant investigation with antiarrhythmic drugs. The lack of efficacy and the proarrhythmic effects of drugs catalyzed the development and investigation of the ICD through several major clinical trials that proved the efficacy of ICD as a bedrock tool to detect and promptly treat life-threatening arrhythmias. The ICD therapy is routinely used for primary prevention of SCD in patients with cardiomyopathy and high risk inherited arrhythmic conditions and secondary prevention in survivors of sudden cardiac arrest. This compendium will review the clinical management of those surviving SCD and discuss landmark studies of antiarrhythmic drugs, ICD, and cardiac resynchronization therapy in the primary and secondary prevention of SCD.

Original languageEnglish (US)
Pages (from-to)2020-2040
Number of pages21
JournalCirculation Research
Volume116
Issue number12
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Sudden Cardiac Death
Implantable Defibrillators
Anti-Arrhythmia Agents
Primary Prevention
Secondary Prevention
Survivors
Cardiac Arrhythmias
Cardiac Resynchronization Therapy
Catheter Ablation
Therapeutics
Sudden Death
Cardiomyopathies
Tachycardia
Stroke Volume
Public Health
Clinical Trials
Recurrence
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • cardiac resynchronization therapy
  • cardiomyopathies
  • death, sudden, cardiac
  • defibrillators
  • defibrillators, implantable
  • heart arrest
  • tachycardia, ventricular
  • ventricular fibrillation

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Clinical Management and Prevention of Sudden Cardiac Death. / Yousuf, Omair; Chrispin, Jonathan; Tomaselli, Gordon F.; Berger, Ronald D.

In: Circulation Research, Vol. 116, No. 12, 01.01.2015, p. 2020-2040.

Research output: Contribution to journalArticle

Yousuf, Omair ; Chrispin, Jonathan ; Tomaselli, Gordon F. ; Berger, Ronald D. / Clinical Management and Prevention of Sudden Cardiac Death. In: Circulation Research. 2015 ; Vol. 116, No. 12. pp. 2020-2040.
@article{9417ef92790d4cc3bb860b1cca5f8153,
title = "Clinical Management and Prevention of Sudden Cardiac Death",
abstract = "Despite the revolutionary advancements in the past 3 decades in the treatment of ventricular tachyarrhythmias with device-based therapy, sudden cardiac death (SCD) remains an enormous public health burden. Survivors of SCD are generally at high risk for recurrent events. The clinical management of such patients requires a multidisciplinary approach from postresuscitative care to a thorough cardiovascular investigation in an attempt to identify the underlying substrate, with potential to eliminate or modify the triggers through catheter ablation and ultimately an implantable cardioverter-defibrillator (ICD) for prompt treatment of recurrences in those at risk. Early recognition of low left ventricular ejection fraction as a strong predictor of death and association of ventricular arrhythmias with sudden death led to significant investigation with antiarrhythmic drugs. The lack of efficacy and the proarrhythmic effects of drugs catalyzed the development and investigation of the ICD through several major clinical trials that proved the efficacy of ICD as a bedrock tool to detect and promptly treat life-threatening arrhythmias. The ICD therapy is routinely used for primary prevention of SCD in patients with cardiomyopathy and high risk inherited arrhythmic conditions and secondary prevention in survivors of sudden cardiac arrest. This compendium will review the clinical management of those surviving SCD and discuss landmark studies of antiarrhythmic drugs, ICD, and cardiac resynchronization therapy in the primary and secondary prevention of SCD.",
keywords = "cardiac resynchronization therapy, cardiomyopathies, death, sudden, cardiac, defibrillators, defibrillators, implantable, heart arrest, tachycardia, ventricular, ventricular fibrillation",
author = "Omair Yousuf and Jonathan Chrispin and Tomaselli, {Gordon F.} and Berger, {Ronald D.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1161/CIRCRESAHA.116.304555",
language = "English (US)",
volume = "116",
pages = "2020--2040",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Clinical Management and Prevention of Sudden Cardiac Death

AU - Yousuf, Omair

AU - Chrispin, Jonathan

AU - Tomaselli, Gordon F.

AU - Berger, Ronald D.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Despite the revolutionary advancements in the past 3 decades in the treatment of ventricular tachyarrhythmias with device-based therapy, sudden cardiac death (SCD) remains an enormous public health burden. Survivors of SCD are generally at high risk for recurrent events. The clinical management of such patients requires a multidisciplinary approach from postresuscitative care to a thorough cardiovascular investigation in an attempt to identify the underlying substrate, with potential to eliminate or modify the triggers through catheter ablation and ultimately an implantable cardioverter-defibrillator (ICD) for prompt treatment of recurrences in those at risk. Early recognition of low left ventricular ejection fraction as a strong predictor of death and association of ventricular arrhythmias with sudden death led to significant investigation with antiarrhythmic drugs. The lack of efficacy and the proarrhythmic effects of drugs catalyzed the development and investigation of the ICD through several major clinical trials that proved the efficacy of ICD as a bedrock tool to detect and promptly treat life-threatening arrhythmias. The ICD therapy is routinely used for primary prevention of SCD in patients with cardiomyopathy and high risk inherited arrhythmic conditions and secondary prevention in survivors of sudden cardiac arrest. This compendium will review the clinical management of those surviving SCD and discuss landmark studies of antiarrhythmic drugs, ICD, and cardiac resynchronization therapy in the primary and secondary prevention of SCD.

AB - Despite the revolutionary advancements in the past 3 decades in the treatment of ventricular tachyarrhythmias with device-based therapy, sudden cardiac death (SCD) remains an enormous public health burden. Survivors of SCD are generally at high risk for recurrent events. The clinical management of such patients requires a multidisciplinary approach from postresuscitative care to a thorough cardiovascular investigation in an attempt to identify the underlying substrate, with potential to eliminate or modify the triggers through catheter ablation and ultimately an implantable cardioverter-defibrillator (ICD) for prompt treatment of recurrences in those at risk. Early recognition of low left ventricular ejection fraction as a strong predictor of death and association of ventricular arrhythmias with sudden death led to significant investigation with antiarrhythmic drugs. The lack of efficacy and the proarrhythmic effects of drugs catalyzed the development and investigation of the ICD through several major clinical trials that proved the efficacy of ICD as a bedrock tool to detect and promptly treat life-threatening arrhythmias. The ICD therapy is routinely used for primary prevention of SCD in patients with cardiomyopathy and high risk inherited arrhythmic conditions and secondary prevention in survivors of sudden cardiac arrest. This compendium will review the clinical management of those surviving SCD and discuss landmark studies of antiarrhythmic drugs, ICD, and cardiac resynchronization therapy in the primary and secondary prevention of SCD.

KW - cardiac resynchronization therapy

KW - cardiomyopathies

KW - death, sudden, cardiac

KW - defibrillators

KW - defibrillators, implantable

KW - heart arrest

KW - tachycardia, ventricular

KW - ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=84938905438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938905438&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.116.304555

DO - 10.1161/CIRCRESAHA.116.304555

M3 - Article

C2 - 26044254

AN - SCOPUS:84938905438

VL - 116

SP - 2020

EP - 2040

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 12

ER -